Biomarkers for Predicting Clinical Deterioration in Schizophrenia-Spectrum Disorders: A Systematic Review
Brain Sciences · 22.05.2026 · 16 (6) · 550
DOI: 10.3390/brainsci16060550 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Brain Sciences, online erschienen am 22.05.2026. Verfasst von Valerio Ricci und 5 weiteren Autor:innen. Beteiligte Einrichtung: San Luigi Gonzaga Hospital, University of Turin, Regione Gonzole, 10, 10043 Orbassano, Italy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Psychotic relapse affects over 80% of individuals with schizophrenia-spectrum disorders, driving long-term disability and hospitalization. Clinical relapse management relies on symptomatic monitoring without objective neurobiological tools to guide individualized antipsychotic decisions.
Methods
This systematic review synthesizes evidence on neurophysiological, blood-based, molecular, neuroimaging, and digital biomarkers for relapse prediction in schizophrenia-spectrum disorders.
Results
Following the PRISMA 2020 guidelines, five databases were searched through March 2026 for longitudinal biomarker studies. Quality was assessed using the Newcastle-Ottawa Scale and PROBAST; findings were synthesized narratively due to substantial heterogeneity. From the 6812 citations screened, 21 studies were included across clinical high-risk, first-episode, and established illness populations.
Conclusions
Mismatch negativity and P300 event-related potential (P300) showed the most consistent associations with relapse vulnerability, with mismatch negativity demonstrating relative independence from antipsychotic effects. Inflammatory and neuroendocrine markers—interleukin-6, C-reactive protein, and cortisol awakening response—predicted poor treatment response in multiple longitudinal investigations. Peripheral blood gene expression profiling identified TCF4 network dysregulation as a candidate molecular marker of impending relapse. Neuroimaging models did not outperform standard clinical variables. Digital phenotyping showed ecological promise but remains methodologically nascent. No single biomarker achieves sufficient accuracy for clinical implementation. Neurophysiological and inflammatory markers are the most tractable candidates for monitoring protocols. Future research should prioritize multimodal longitudinal designs, external validation, and systematic antipsychotic confounding control. Among the biomarkers reviewed, mismatch negativity and the interleukin-6/cortisol awakening response combination represent the most tractable candidates for pilot clinical implementation, particularly in specialized early psychosis services and antipsychotic dose-reduction research contexts; no biomarker currently achieves sufficient accuracy for routine use in maintenance treatment decisions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- San Luigi Gonzaga Hospital, University of Turin, Regione Gonzole, 10, 10043 Orbassano, Italy.
- Department of Neurosciences "Rita Levi Montalcini", University of Turin, Via Cherasco 15, 10126 Torino, Italy.
- Department of Neurosciences, Imaging and Clinical Sciences, Università degli Studi G. D'Annunzio Chieti-Pescara, 66100 Chieti, Italy.
ORCID-Profile: Valerio Ricci, Giovanni Martinotti, Giuseppe Maina
Zitieren
APA
Ricci, V., Sarni, A., Barresi, M., Remondino, L., Martinotti, G., & Maina, G. (2026). Biomarkers for Predicting Clinical Deterioration in Schizophrenia-Spectrum Disorders: A Systematic Review. Brain Sciences, 16(6), 550. https://doi.org/10.3390/brainsci16060550
Vancouver
Ricci V, Sarni A, Barresi M, Remondino L, Martinotti G, Maina G. Biomarkers for Predicting Clinical Deterioration in Schizophrenia-Spectrum Disorders: A Systematic Review. Brain Sciences. 2026;16(6):550. doi:10.3390/brainsci16060550
BibTeX
@article{Ricci2026,
author = {Ricci, Valerio and Sarni, Alessandro and Barresi, Marialuigia and Remondino, Lorenzo and Martinotti, Giovanni and Maina, Giuseppe},
title = {Biomarkers for Predicting Clinical Deterioration in Schizophrenia-Spectrum Disorders: A Systematic Review},
journal = {Brain Sciences},
year = {2026},
volume = {16},
number = {6},
pages = {550},
doi = {10.3390/brainsci16060550}
}
EUVIMED